18612909. LASER AND BCL-2 INHIBITORS COMBINATION TO TREAT SOLID TUMORS simplified abstract (Board of Regents, The University of Texas System)

LASER AND BCL-2 INHIBITORS COMBINATION TO TREAT SOLID TUMORS

Organization Name

Board of Regents, The University of Texas System

Inventor(s)

Md Nurunnabi of El Paso TX (US)

Himanshu Bhatt of El Paso TX (US)

LASER AND BCL-2 INHIBITORS COMBINATION TO TREAT SOLID TUMORS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18612909 titled 'LASER AND BCL-2 INHIBITORS COMBINATION TO TREAT SOLID TUMORS

Simplified Explanation:

The patent application involves treating solid tumors by administering a compound containing a BCL-2/BCL-xl inhibitor chemically bonded to a 2D nanosheet, such as Navitoclax deposited on boron nitride nanosheets to form a nanosphere via π-π stacking.

• The compound includes a BCL-2/BCL-xl inhibitor chemically bonded to a 2D nanosheet.
• Navitoclax is deposited on boron nitride nanosheets to form a nanosphere via π-π stacking.

Potential Applications:

This technology could be used in the treatment of solid tumors in mammals, potentially improving the efficacy of current treatments.

Problems Solved:

This technology addresses the challenge of effectively targeting and treating solid tumors in mammals.

Benefits:

The compound's unique structure and delivery method could enhance the effectiveness of tumor treatment, potentially leading to better outcomes for patients.

Commercial Applications:

- Title: Innovative Solid Tumor Treatment Compound - This technology could have significant commercial applications in the pharmaceutical industry for developing new cancer treatments. - It may also have implications for research and development in the field of nanomedicine.

Prior Art:

Readers interested in prior art related to this technology could explore research on nanosheet-based drug delivery systems and BCL-2/BCL-xl inhibitors in cancer treatment.

Frequently Updated Research:

Researchers are continually exploring new ways to improve cancer treatment through nanotechnology and targeted drug delivery systems.

Questions about Solid Tumor Treatment with BCL-2/BCL-xl Inhibitor Nanosheets: 1. How does the chemical bonding of BCL-2/BCL-xl inhibitors to 2D nanosheets enhance tumor treatment? 2. What are the potential challenges in scaling up the production of nanosphere compounds for clinical use?

Original Abstract Submitted

Treating solid tumors includes administering to a mammal in need of treatment a compound including at least one BCL-2/BCL-xl inhibitor chemically bonded on a 2D nanosheet. The compound can include Navitoclax deposited on 2D nanosheets of boron nitride to form a nanosphere via π-π stacking.